Department of Oncology, Ivano-Frankiv National Medical University, Ivano-Frankivsk, 76018, Ukraine.
Laboratory of Immunology & Molecular Biology, O'Bogomolets National Medical University, Kyiv, 01601, Ukraine.
Immunotherapy. 2024;16(13):869-878. doi: 10.1080/1750743X.2024.2376517. Epub 2024 Aug 19.
Patients with cancer of the oral cavity and oropharynx (COCO) often exhibit signs of immunosuppression, affecting their prognosis. Understanding the dynamics of humoral immunity in these patients during chemoradiation therapy is crucial for developing effective treatments. This prospective study included 105 COCO patients undergoing different treatment regimens, with or without alpha/beta-defensins therapy. Serum concentrations of IgG, IgM, IgA and salivary sIgA were analyzed. Patients were divided into five groups based on treatment protocols. Treatment variations impacted serum immunoglobulin levels, notably in Group III, whose patients received radiation treatment and immunotherapy with higher alpha/beta-defensins doses. Significant IgG changes correlated with oral mucositis risk and outcomes. Further trials are necessary for validation and clinical application.
口腔和口咽癌（COCO）患者常表现出免疫抑制迹象，影响其预后。了解这些患者在放化疗期间体液免疫的动态变化对于开发有效的治疗方法至关重要。这项前瞻性研究纳入了 105 名接受不同治疗方案的 COCO 患者，其中部分患者接受了 α/β-防御素治疗。分析了 IgG、IgM、IgA 和唾液 sIgA 的血清浓度。根据治疗方案将患者分为五组。治疗方案的差异影响了血清免疫球蛋白水平，特别是在接受放射治疗和免疫治疗且 α/β-防御素剂量较高的 III 组患者中。IgG 的显著变化与口腔粘膜炎的风险和结果相关。需要进一步的试验来验证和临床应用。
